BEGIN:VCALENDAR VERSION:2.0 PRODID:-//jEvents 2.0 for Joomla//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT UID:baf9d56fe8638debb6e9514fa4300111 CATEGORIES:Seminar CREATED:20180117T191203 SUMMARY:Professor Mari Dezawa DESCRIPTION:Professor Mari DezawaTohoku UniversityTuesday April 3, 2018\n12:00PM, Life Sciences Auditorium\n“Endogenous Reparative Muse Cells Provide the Concept of Next-Generation Medical Treatment”\nMultilineage-differentiating stress enduring (Muse) cells are naturally existing unique endogenous stem cells t hat are non-tumorigenic and are pluripotent-like. They express pluripotent markers, can generate cells representative of all three germ layers from a single cell and are able to self-renew. Since they express specific recepto r for damage signal, sphingosine-1-phosphate (S1P receptor2), they can pref erentially home into S1P-producing damaged site after intravenous injection with lower entrapment in the lung and spleen. After integration, they\nrep lenish lost cells by spontaneous differentiation into tissue-compatible cel ls, leading to robust tissue and functional regeneration. The unique repara tive functions of Muse cells were\ndemonstrated in animal models of liver c irrhosis, stroke, chronic kidney disease and acute myocardial infarction (A MI). They do not have to be “induced,” or genetically manipulated, to be pl uripotent or be purposive cells before administration. They can be collecte d as cells positive for SSEA-3, a surface marker for pluripotent stem cells , from readily accessible sources such as the bone marrow (~0.03% of the to tal mononucleated cell population), and from commercially available culture d fibroblasts (several %). Recently, Muse cells are shown to circulate in p eripheral blood in healthy donors, and the number increases in stroke and A MI patients in an acute phase, suggesting that endogenous Muse cells are mo bilized into peripheral blood to repair tissues while their number is not s ufficient to recover, and that supply of exogenous Muse cells is expected t o deliver statistically meaningful functional recovery. Overall, Muse cells are a feasible source for cell-based approaches?and may safely provide cli nically relevant regenerative effects compatible with the ‘body’s natural\n repair systems’ by simple cost-effective strategy-collection of Muse cells from sources, large scale expansion and intravenous injection. Currently, t he phase I clinical study targeting AMI is conducted by Mitsubishi Chemical Holdings.\n~Coffee/tea will be served prior to lecture~\n X-ALT-DESC;FMTTYPE=text/html:
Tuesday April 3, 2018
12:00PM, Life Sciences Auditorium
“Endoge nous Reparative Muse Cells Provide the Concept of Next-Generation Medical T reatment”
Multilineage-differentiating stress enduring (Muse) cells a
re naturally existing unique endogenous stem cells that are non-tumori
genic and are pluripotent-like. They express pluripotent markers, can
generate cells representative of all three germ layers from a single cell a
nd are able to self-renew. Since they express specific receptor for damage
signal, sphingosine-1-phosphate (S1P receptor2), they can preferentially ho
me into S1P-producing damaged site after intravenous injection with lower e
ntrapment in the lung and spleen. After integration, they
replenish lo
st cells by spontaneous differentiation into tissue-compatible cells, leadi
ng to robust tissue and functional regeneration. The unique reparative func
tions of Muse cells were
demonstrated in animal models of liver cirrho
sis, stroke, chronic kidney disease and acute myocardial infarction (A
MI). They do not have to be “induced,” or genetically manipulated, to be pl
uripotent or be purposive cells before administration. They can be collecte
d as cells positive for SSEA-3, a surface marker for pluripotent stem cells
, from readily accessible sources such as the bone marrow (~0.03% of the to
tal mononucleated cell population), and from commercially available culture
d fibroblasts (several %). Recently, Muse cells are shown to circulate in p
eripheral blood in healthy donors, and the number increases in stroke
and AMI patients in an acute phase, suggesting that endogenous Muse cells a
re mobilized into peripheral blood to repair tissues while their number is
not sufficient to recover, and that supply of exogenous Muse cells is
expected to deliver statistically meaningful functional recovery. Overall,
Muse cells are a feasible source for cell-based approaches?and may safely p
rovide clinically relevant regenerative effects compatible with the ‘body’s
natural
repair systems’ by simple cost-effective strategy-collection
of Muse cells from sources, large scale expansion and intravenous injection
. Currently, the phase I clinical study targeting AMI is conducted by Mitsu
bishi Chemical Holdings.
~Coffee/tea will be served prior to lecture~
DTSTAMP:20240329T133042 DTSTART:20180403T160000 DTEND:20180403T170000 SEQUENCE:0 TRANSP:OPAQUE END:VEVENT END:VCALENDAR